FATE Fate Therapeutics, Inc. Stock Quote

FATE [NASD]

Index	-	P/E	-	EPS (ttm)	-1.85	Insider Own	0.70%	Shs Outstand	86.89M	Perf Week	-21.87%
Market Cap	8.44B	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-21.43%	Shs Float	73.79M	Perf Month	-11.40%
Income	-148.60M	PEG	-	EPS next Q	-0.39	Inst Own	95.60%	Short Float	14.97%	Perf Quarter	84.68%
Sales	18.30M	P/S	461.09	EPS this Y	-21.50%	Inst Trans	0.08%	Short Ratio	9.61	Perf Half Y	168.60%
Book/sh	4.88	P/B	18.30	EPS next Y	1.10%	ROA	-31.20%	Target Price	88.69	Perf Year	267.08%
Cash/sh	5.17	P/C	17.26	EPS next 5Y	-	ROE	-43.60%	52W Range	16.75 - 121.16	Perf YTD	-1.78%
Dividend	-	P/FCF	-	EPS past 5Y	-2.60%	ROI	-41.10%	52W High	-26.29%	Beta	1.69
Dividend %	-	Quick Ratio	9.20	Sales past 5Y	-	Gross Margin	-	52W Low	433.19%	ATR	7.29
Employees	178	Current Ratio	9.20	Sales Q/Q	216.70%	Oper. Margin	-	RSI (14)	41.38	Volatility	9.08% 7.56%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-69.90%	Profit Margin	-	Rel Volume	0.74	Prev Close	96.14
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 05 AMC	Payout	-	Avg Volume	1.15M	Price	89.31
Recom	1.70	SMA20	-13.59%	SMA50	5.78%	SMA200	87.19%	Volume	855,309	Change	-7.10%

May-13-20

Initiated

H.C. Wainwright

Buy

$42

Mar-04-20

Initiated

Barclays

Overweight

$40

Jan-09-20

Downgrade

BMO Capital Markets

Outperform → Market Perform

$22

Dec-30-19

Reiterated

Mizuho

Buy

$27 → $33

Dec-09-19

Upgrade

Wells Fargo

Market Perform → Outperform

Nov-12-19

Initiated

SunTrust

Buy

$25

Nov-06-19

Downgrade

Wells Fargo

Outperform → Market Perform

Oct-01-19

Initiated

Stifel

Buy

$27

Aug-09-19

Initiated

BTIG Research

Buy

$27

Jul-22-19

Initiated

Cantor Fitzgerald

Overweight

Jul-12-19

Initiated

Oppenheimer

Outperform

$27

Jun-13-19

Initiated

Mizuho

Buy

Jun-07-19

Initiated

ROTH Capital

Neutral

$20

May-31-19

Initiated

Guggenheim

Buy

May-24-19

Resumed

Citigroup

Buy

$26

Mar-28-19

Initiated

SVB Leerink

Outperform

$20

Jan-03-19

Downgrade

Stephens

Overweight → Equal-Weight

Nov-05-18

Initiated

Jefferies

Buy

Aug-01-18

Initiated

Citigroup

Buy

$20

Mar-06-18

Downgrade

H.C. Wainwright

Buy → Neutral

$12

Jan-11-21 08:02AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals Zacks
Jan-08-21 04:26PM	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
09:01AM	CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update Zacks
08:50AM	Is the Options Market Predicting a Spike in Fate Therapeutics (FATE) Stock? Zacks
Jan-07-21 04:24PM	Genetics Stocks Pop After Intellia Offers Update For Gene-Editing Drugs Investor's Business Daily +17.48%
Jan-06-21 12:30AM	Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire +15.06%
Jan-05-21 06:23AM	3 Biotech Stocks That Could Double Your Money in 2021 Motley Fool
Jan-04-21 04:01PM	Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock GlobeNewswire
Dec-30-20 10:42AM	The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana Therapeutics Zacks
07:18AM	Here's a Cancer-Killing Stock to Buy for 2021 Motley Fool
Dec-29-20 09:37AM	5 Biotech Stocks That Have Gained More Than 200% in 2020 Zacks
Dec-28-20 10:43AM	FATE Surges More Than 152% in Three Months: Here's Why? Zacks
Dec-23-20 09:21AM	Here's Why Fate Therapeutics' Data Produced a 38% Jump in the Stock Price Motley Fool
Dec-22-20 04:30PM	Is FATE A Good Stock To Buy According To Hedge Funds? Insider Monkey +7.33%
Dec-09-20 08:42AM	Fate Therapeutics (FATE) Looks Good: Stock Adds 9.4% in Session Zacks -5.46%
Dec-08-20 01:22PM	Fate (FATE) Surges on Favorable Phase I Data on FT596 at ASH Zacks +9.35%
Dec-07-20 04:20PM	Here Are The Winners Of This Year's Biggest Blood Cancer Meeting Investor's Business Daily +37.80%
03:33PM	Fate Stock Soars After Novel Natural-Killer Treatment for Cancers Makes a Splash Barrons.com
12:39PM	Why Fate Therapeutics Stock Is Skyrocketing Today Motley Fool
10:00AM	Traders Sift Through Biotech Winners and Losers After Hematology Meeting Bloomberg
Dec-06-20 10:05AM	Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma GlobeNewswire
Dec-05-20 11:32AM	Why Is Fate Therapeutics (FATE) Up 21.8% Since Last Earnings Report? Zacks
Dec-04-20 04:01PM	Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma GlobeNewswire
10:43AM	Red-Hot Biotechs to Take Spotlight at Blood Disorder Meeting Bloomberg
Nov-30-20 08:00AM	Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting GlobeNewswire
Nov-12-20 04:01PM	Fate Therapeutics Announces Participation in Upcoming Investor Conferences GlobeNewswire
Nov-10-20 05:54AM	Growth Investors: Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 25% Simply Wall St.
Nov-07-20 02:00AM	Fate Therapeutics Inc (FATE) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 06:05PM	Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:01PM	Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress GlobeNewswire
03:45PM	Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
08:00AM	Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting GlobeNewswire
Nov-03-20 09:15AM	Were Hedge Funds Right About Loading Up On Fate Therapeutics Inc (FATE)? Insider Monkey
Nov-02-20 07:00AM	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results GlobeNewswire
Oct-15-20 08:00AM	Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting GlobeNewswire
Sep-30-20 08:00AM	Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit GlobeNewswire
Sep-11-20 10:11AM	Hedge Funds Are Absolutely Crazy About Fate Therapeutics Inc (FATE) Insider Monkey +5.73%
Sep-04-20 08:00AM	Fate Therapeutics Announces September Investor Events GlobeNewswire
Aug-19-20 08:00AM	Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer GlobeNewswire
Aug-11-20 08:19AM	What Kind Of Shareholders Own Fate Therapeutics, Inc. (NASDAQ:FATE)? Simply Wall St.
08:00AM	How Much Of Fate Therapeutics, Inc. (NASDAQ:FATE) Do Institutions Own? Simply Wall St.
Aug-05-20 05:55PM	Fate Therapeutics (FATE) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:01PM	Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress GlobeNewswire
Aug-04-20 04:01PM	Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire
Jul-29-20 04:01PM	Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results GlobeNewswire
Jul-28-20 12:32PM	Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -6.20%
Jul-26-20 07:40AM	Could Fate Therapeutics Be a Millionaire-Maker Stock? Motley Fool
Jul-21-20 08:11AM	2 Stocks to Hold for the Next 20 Years Motley Fool
Jul-16-20 11:06AM	Were Hedge Funds Right About Piling Into Fate Therapeutics Inc (FATE)? Insider Monkey
Jul-14-20 08:00AM	Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies GlobeNewswire
Jul-10-20 10:18AM	Fate's IND Application for CAR T Cell Therapy Gets FDA Nod Zacks
Jul-09-20 08:00AM	Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy GlobeNewswire
Jun-15-20 10:50PM	Edited Transcript of FATE.OQ earnings conference call or presentation 11-May-20 9:00pm GMT Thomson Reuters StreetEvents
01:44PM	Hedge Funds Keep Buying Fate Therapeutics Inc (FATE) Insider Monkey
Jun-13-20 07:50AM	If You Invested $1,000 in Fate Therapeutics' IPO, This Is How Much Money You'd Have Now Motley Fool
Jun-11-20 04:01PM	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -9.52%
Jun-09-20 05:29PM	Here's Why Fate Therapeutics Rose 18.4% in May Motley Fool +15.58%
02:10PM	Here's Why Fate Therapeutics Stock Jumped Higher Today Motley Fool
12:49AM	Fate Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jun-08-20 04:01PM	Fate Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
May-20-20 08:00AM	Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy GlobeNewswire +7.38%
May-15-20 06:18AM	Here's Why Big Buyers Are Excited About This Cancer Immunotherapy Stock Motley Fool +6.87%
May-12-20 04:30PM	Fate Therapeutics Inc (FATE) Q1 2020 Earnings Call Transcript Motley Fool
01:40PM	Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering Barrons.com
May-11-20 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:01PM	Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress GlobeNewswire
May-08-20 08:46AM	Should You Buy Fate Therapeutics (FATE) Ahead of Earnings? Zacks
May-05-20 09:18PM	Were Hedge Funds Right About Fate Therapeutics Inc (FATE)? Insider Monkey
04:01PM	Fate Therapeutics Announces Changes to its Board of Directors GlobeNewswire
May-04-20 04:01PM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2020 Financial Results GlobeNewswire +7.00%
09:38AM	Why Earnings Season Could Be Great for Fate Therapeutics (FATE) Zacks
Apr-30-20 08:33AM	3 Monster Growth Stocks With Still Plenty of Gas in the Tank TipRanks -5.65%
Apr-29-20 07:11AM	Is Fate Therapeutics a Buy? Motley Fool
Apr-28-20 04:30PM	Fate Therapeutics Announces Preclinical Data Presentation of Novel CAR MICA/B Cell-based Cancer Immunotherapy Program at the 2020 ASGCT Annual Meeting GlobeNewswire -7.37%
12:33PM	Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Apr-14-20 09:13AM	Top Ranked Momentum Stocks to Buy for April 14th Zacks +7.39%
Apr-10-20 12:00PM	Fate Therapeutics (FATE) is a Great Momentum Stock: Should You Buy? Zacks
Apr-08-20 11:30AM	Is Fate Therapeutics (FATE) Stock Outpacing Its Medical Peers This Year? Zacks +6.00%
10:05AM	Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More Zacks
10:04AM	Is Fate Therapeutics (FATE) Stock a Solid Choice Right Now? Zacks
Apr-06-20 09:08AM	Fate Therapeutics (FATE) Looks Good: Stock Adds 8.9% in Session Zacks +8.11%
Apr-04-20 09:07AM	Growth Investors: Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 13% Simply Wall St.
Apr-03-20 06:34PM	7 Biotech Stocks to Buy for a Post-Pandemic World Barrons.com +8.88%
04:20PM	Small Biotech Jumps On $100 Million Cancer Deal With Pharma Giant J&J Investor's Business Daily
10:57AM	Fate Therapeutics Surges on Immunotherapy Deal With J&J Zacks
07:36AM	The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO Benzinga
Apr-02-20 04:46PM	Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies GlobeNewswire
04:45PM	Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update GlobeNewswire
Mar-25-20 09:04AM	Edited Transcript of FATE earnings conference call or presentation 2-Mar-20 10:00pm GMT Thomson Reuters StreetEvents
Mar-17-20 10:24AM	Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock? Zacks +28.47%
Mar-02-20 05:15PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates Zacks +6.20%
04:01PM	Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook GlobeNewswire
Feb-29-20 02:52PM	The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off Benzinga
Feb-26-20 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-25-20 12:30PM	Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-07-20 08:00AM	Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Feb-05-20 11:52AM	Steven Cohen Renews His Interest in Verastem GuruFocus.com
Jan-16-20 06:15AM	Fate Therapeutics (NASDAQ:FATE) Shareholders Have Enjoyed A Whopping 682% Share Price Gain Simply Wall St.
Jan-13-20 08:00AM	Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood GlobeNewswire
Jan-03-20 10:44AM	3 Top Drug Stocks to Own In 2020 InvestorPlace

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wolchko J Scott	President and CEO	Jan 22	Option Exercise	5.32	30,000	159,700	423,793	Jan 22 06:23 PM
Wolchko J Scott	President and CEO	Jan 22	Sale	98.29	30,000	2,948,611	393,793	Jan 22 06:23 PM
Wolchko J Scott	President and CEO	Jan 21	Option Exercise	2.73	30,000	81,900	423,793	Jan 22 06:23 PM
Wolchko J Scott	President and CEO	Jan 21	Sale	103.05	30,000	3,091,357	393,793	Jan 22 06:23 PM
TAHL CINDY	General Counsel and Secretary	Jan 19	Option Exercise	2.90	35,000	101,500	125,035	Jan 21 07:08 PM
TAHL CINDY	General Counsel and Secretary	Jan 19	Sale	114.76	35,000	4,016,639	90,035	Jan 21 07:08 PM
Shoemaker Daniel D	Chief Scientific Officer	Jan 11	Sale	110.81	3,253	360,477	83,609	Jan 12 08:38 PM
TAHL CINDY	General Counsel and Secretary	Jan 11	Sale	110.81	3,254	360,587	90,035	Jan 12 08:39 PM
Valamehr Bahram	Chief Development Officer	Jan 11	Sale	110.81	3,254	360,588	77,727	Jan 12 08:40 PM
Wolchko J Scott	President and CEO	Jan 11	Sale	110.81	8,587	951,556	350,562	Jan 12 08:41 PM
Redmile Group, LLC	Director	Jan 08	Buy	85.50	327,485	27,999,968	12,957,222	Jan 12 04:16 PM
Wolchko J Scott	President and CEO	Jan 08	Sale	117.10	60,820	7,122,217	359,149	Jan 12 08:41 PM
Valamehr Bahram	Chief Development Officer	Jan 08	Sale	117.10	6,230	729,552	80,981	Jan 12 08:40 PM
TAHL CINDY	General Counsel and Secretary	Jan 08	Sale	117.10	6,229	729,434	93,289	Jan 12 08:39 PM
Shoemaker Daniel D	Chief Scientific Officer	Jan 08	Sale	117.10	6,229	729,434	86,862	Jan 12 08:38 PM
Wolchko J Scott	President and CEO	Dec 17	Option Exercise	6.62	20,000	132,400	439,969	Dec 18 04:01 PM
Wolchko J Scott	President and CEO	Dec 17	Sale	91.82	20,000	1,836,352	419,969	Dec 18 04:01 PM
Valamehr Bahram	Chief Development Officer	Dec 14	Option Exercise	2.90	25,000	72,500	112,211	Dec 15 04:01 PM
Valamehr Bahram	Chief Development Officer	Dec 14	Sale	97.78	25,000	2,444,477	87,211	Dec 15 04:01 PM
Shoemaker Daniel D	Chief Scientific Officer	Nov 16	Sale	51.83	25,000	1,295,746	93,091	Nov 16 05:12 PM
Wolchko J Scott	President and CEO	Nov 13	Option Exercise	5.73	30,000	172,008	430,123	Nov 16 04:02 PM
Wolchko J Scott	President and CEO	Nov 13	Sale	51.03	30,000	1,530,900	419,969	Nov 16 04:02 PM
Wolchko J Scott	President and CEO	Nov 12	Option Exercise	2.73	30,000	81,900	449,969	Nov 16 04:02 PM
Wolchko J Scott	President and CEO	Nov 12	Sale	52.72	30,000	1,581,524	419,969	Nov 16 04:02 PM
TAHL CINDY	General Counsel and Secretary	Nov 05	Option Exercise	2.82	19,282	54,340	118,800	Nov 06 04:02 PM
TAHL CINDY	General Counsel and Secretary	Nov 05	Sale	50.63	19,282	976,252	99,518	Nov 06 04:02 PM
TAHL CINDY	General Counsel and Secretary	Nov 04	Option Exercise	2.73	51,519	140,647	151,037	Nov 06 04:02 PM
TAHL CINDY	General Counsel and Secretary	Nov 04	Sale	50.41	51,519	2,597,140	99,518	Nov 06 04:02 PM
TAHL CINDY	General Counsel and Secretary	Oct 16	Option Exercise	2.73	29,199	79,713	128,717	Oct 20 04:01 PM
TAHL CINDY	General Counsel and Secretary	Oct 16	Sale	50.25	29,199	1,467,212	99,518	Oct 20 04:01 PM
TAHL CINDY	General Counsel and Secretary	Oct 01	Option Exercise	2.73	35,000	95,550	134,518	Oct 02 04:01 PM
TAHL CINDY	General Counsel and Secretary	Oct 01	Sale	40.74	35,000	1,426,065	99,518	Oct 02 04:01 PM
Valamehr Bahram	Chief Development Officer	Sep 14	Option Exercise	2.75	25,000	68,778	112,211	Sep 16 04:02 PM
Shoemaker Daniel D	Chief Scientific Officer	Sep 14	Sale	36.30	25,000	907,540	118,091	Sep 16 04:01 PM
Valamehr Bahram	Chief Development Officer	Sep 14	Sale	36.28	25,000	907,024	87,211	Sep 16 04:02 PM
Redmile Group, LLC	Director	Jun 11	Buy	28.31	1,412,928	39,999,992	12,629,737	Jun 17 08:25 PM
RASTETTER WILLIAM H	Director	Mar 30	Option Exercise	1.37	28,461	38,992	28,461	Mar 31 04:01 PM
Valamehr Bahram	Chief Development Officer	Feb 03	Option Exercise	1.69	1,153	1,949	87,211	Feb 04 04:01 PM
Wolchko J Scott	President and CEO	Jan 30	Option Exercise	2.70	25,000	67,500	444,969	Feb 03 04:01 PM
Wolchko J Scott	President and CEO	Jan 30	Sale	25.45	25,000	636,303	419,969	Feb 03 04:01 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience